EANM launches new award to accelerate alpha radioligand therapy research
The European Association of Nuclear Medicine (EANM) invites applications from early-career nuclear medicine researchers working on prostate cancer. Winners will be announced at the EANM’26 Congress.
[Vienna, 23 February, 2026] — Applications are now open for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced Accelerator Applications (a Novartis company), aims to accelerate innovative research in alpha radioligand therapy (α-RLT) in prostate cancer. Winners will be recognised across three award categories: Platinum (40,000 euros), Gold (20,000 euros), and Silver (10,000 euros) awards.
“Alpha radioligand therapy is rapidly emerging as a transformative frontier in precision oncology, and we strongly believe in the talent of researchers at the beginning of their careers in this field,” says EANM President Paola Anna Erba. “This award was designed to nurture their growth by pairing research excellence with structured training, mentorship, and collaborative networking opportunities.”
Shaping the Future of Prostate Cancer
EANM invites applications from early career researchers — PhD candidates, postdoctoral fellows, junior faculty, and clinicians-in-training — who are within 10 years of their terminal degree and affiliated with an institution in an EANM member country.
Applicants must submit a project proposal aimed at offering clinically meaningful advances to prostate cancer treatment with the use of α-RLT. Priority areas include optimising clinical use, tailoring the treatment to individual patients, and identifying patients who might benefit the most from it. The deadline for application is May 18, 2026, at 23:59 CEST via ysn@eanm.org.
EANM’26 Congress
Winners will be announced at EANM’26 Congress, held from October 17 to 21 at the Austria Center Vienna (Austria). A dedicated session will give awardees the opportunity to present their projects to an open audience. In addition, they will participate in an interactive workshop with the scientific review committee to further develop their project proposals.
Full information on eligibility and how to apply is available here.
About EANM
EANM is the largest non-profit medical organisation dedicated to nuclear medicine in Europe. It provides a platform to discuss the latest developments in the field. EANM brings together nuclear medicine physicians, medical physicists, radiochemists, pharmacists, technologists, and experts from related fields. EANM works closely with 40 national societies, 20 non-European affiliated societies and international bodies to bring nuclear medicine to the forefront. Each year, the EANM Annual Congress welcomes nuclear medicine professionals from around the world—with a record attendance of more than 9,400 participants in 2025. The next EANM’26 congress will be held in Vienna (Austria) on October 17-21, 2026. In addition, EANM organises other scientific events every year to foster knowledge exchange. In August 2025, EANM also established its own two open-access journals, published as online-only by the world-leading publisher Elsevier.
END
“Alpha radioligand therapy is rapidly emerging as a transformative frontier in precision oncology, and we strongly believe in the talent of researchers at the beginning of their careers in this field,” says EANM President Paola Anna Erba. “This award was designed to nurture their growth by pairing research excellence with structured training, mentorship, and collaborative networking opportunities.”
Shaping the Future of Prostate Cancer
EANM invites applications from early career researchers — PhD candidates, postdoctoral fellows, junior faculty, and clinicians-in-training — who are within 10 years of their terminal degree and affiliated with an institution in an EANM member country.
Applicants must submit a project proposal aimed at offering clinically meaningful advances to prostate cancer treatment with the use of α-RLT. Priority areas include optimising clinical use, tailoring the treatment to individual patients, and identifying patients who might benefit the most from it. The deadline for application is May 18, 2026, at 23:59 CEST via ysn@eanm.org.
EANM’26 Congress
Winners will be announced at EANM’26 Congress, held from October 17 to 21 at the Austria Center Vienna (Austria). A dedicated session will give awardees the opportunity to present their projects to an open audience. In addition, they will participate in an interactive workshop with the scientific review committee to further develop their project proposals.
Full information on eligibility and how to apply is available here.
About EANM
EANM is the largest non-profit medical organisation dedicated to nuclear medicine in Europe. It provides a platform to discuss the latest developments in the field. EANM brings together nuclear medicine physicians, medical physicists, radiochemists, pharmacists, technologists, and experts from related fields. EANM works closely with 40 national societies, 20 non-European affiliated societies and international bodies to bring nuclear medicine to the forefront. Each year, the EANM Annual Congress welcomes nuclear medicine professionals from around the world—with a record attendance of more than 9,400 participants in 2025. The next EANM’26 congress will be held in Vienna (Austria) on October 17-21, 2026. In addition, EANM organises other scientific events every year to foster knowledge exchange. In August 2025, EANM also established its own two open-access journals, published as online-only by the world-leading publisher Elsevier.
END